ReShape Lifesciences (RSLS) Environmental, Social & Governance (ESG) Data

The Company held its Annual Meeting on December 14, 2022.
At the Annual Meeting, the Company’s stockholders approved each of the following proposals set forth in the Proxy Statement:
Proposal 1:
The Company’s stockholders elected Paul F. Hickey as a Class III director to hold office until the 2025 annual meeting of stockholders or until his successor is elected and qualified, or, if sooner, until his death, resignation or removal, as set forth below.
​
Proposal 2:
The Company’s stockholders approved the ReShape Lifesciences Inc. 2022 Equity Incentive Plan, as set forth below.
​
Proposal 3:
The Company’s stockholders authorized the Board, in its discretion but in no event later than December 14, 2023, which is one year after the date of the Annual Meeting, to amend the Company’s Certificate of Incorporation to

effect a reverse stock split of the Company’s common stock, at a ratio in the range of 1-for-30 to 1-for-100, such ratio to be determined by the Board and included in a public announcement, as set forth below.
​
Proposal 4:
The Company’s stockholders approved an amendment to Article IV, Section 1 of the Certificate of Incorporation to increase the number of shares of common stock authorized for issuance to 300,000,000 shares, as set forth below.
​
Proposal 5:
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as set forth below.
​
Proposal 6:
The Company’s stockholders approved, on an advisory basis, a frequency of every one year for future advisory votes on the compensation of the Company’s named executive officers, as set forth below.
​
Proposal 7:
The Company’s stockholders ratified the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022, as set forth below.
​
​